Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
WGGeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS)

NASDAQ Global Market · Currency in USD
$56.15 ▼ -10.99 (-16.37%)
At close: Oct 23, 4:00 PM ET. Market closed.
$61.25 ▲ +5.10 (+9.08%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$67.14
Open
$67.20
Day's Range
$55.00 – $67.40
52 Week Range
$32.21 – $170.87
Volume
2,563,527
Avg. Volume
770,172
Market Cap
$1.67B
Beta (5Y Monthly)
1.97
PE Ratio (TTM)
--
EPS (TTM)
-$3.58
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$81.00

Profile: GeneDx Holdings Corp.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
1,300
CEO
Katherine A. Stueland
Website
genedx.com

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate $0.07 · Revenue est. $122.93M
DateEst.Actual
Aug 3, 2026-$0.19$0.01Beat
May 4, 2026-$0.06-$0.28Miss
Feb 23, 2026$0.11$0.14Beat
Oct 28, 2025$0.28$0.49Beat
Jul 29, 2025$0.10$0.50Beat
Apr 30, 2025$0.11$0.28Beat

Analyst view

Consensus price target
$81.00 ▲ +44.3%
Range $63.00 – $90.00
Rating: Buy
Buy 91% · Hold 9% · Sell 0%

Get free alerts on WGS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.